297.26
-1.91 (-0.64%)
| Previous Close | 299.17 |
| Open | 298.92 |
| Volume | 85,626 |
| Avg. Volume (3M) | 340,060 |
| Market Cap | 6,600,153,088 |
| Price / Sales | 18.65 |
| Price / Book | 14.00 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 4.0 |
| Average | 2.38 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 554.00 (TD Cowen, 86.37%) | Buy |
| Median | 504.00 (69.55%) | |
| Low | 428.00 (Canaccord Genuity, 43.98%) | Buy |
| Average | 497.50 (67.36%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 378.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 26 Aug 2025 | 554.00 (86.37%) | Buy | 424.86 |
| JMP Securities | 20 Aug 2025 | 485.00 (63.16%) | Buy | 391.66 |
| UBS | 12 Aug 2025 | 523.00 (75.94%) | Buy | 359.00 |
| Canaccord Genuity | 06 Aug 2025 | 428.00 (43.98%) | Buy | 338.11 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |